Aevi Genomic Medicine LLC

Aevi Genomic Medicine — Corporate Update (August 2017)

17 slides from Aevi Genomic Medicine's corporate update, Aug 10, 2017

  1. Slide 1: Corporate Update

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine NASDAQ: GNMX Corporate Update August 10, 2017

  2. Slide 2: Forward-Looking Statement

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 2 Forward - Looking Statement This presentation includes certain estimates and other forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to anticipated o

  3. Slide 3: Agenda

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 3 Agenda • Summary of Offering • AEVI - 001 update • AEVI - 002 update • Financial update

  4. Slide 4: Summary Terms of PIPE Offering

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 4 Summary Terms of PIPE Offering • The Children’s Hospital of Philadelphia Foundation (“CHOP Foundation”) leads private placement of $28M – Purchase Price for Common Stock: $1.26 – 3% Premium to 10 Day VWAP prior to and including August 4 – Warrants

  5. Slide 5: Program Overview

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine AEVI - 001 Program Overview

  6. Slide 6: SAGA Trial Summary

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 6 SAGA Trial Summary • Trial did not meet primary endpoint (overall ADHD - RS) 1 , however showed encouraging trend in improvement at highest dose (400 mg BID) – Strong trend of efficacy in ADHD - RS inattention subscale (p=0.0515 vs placebo) • Clear

  7. Slide 7: SAGA Responder Analysis Summary

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 7 SAGA Responder Analysis Summary • Post - hoc analysis of patients responding to AEVI - 001 revealed a 9 - gene subset predictive of response – accounts for approximately 10% of pediatric ADHD patients. 1 • Novel discovery: prevalence of CNTN4 mutat

  8. Slide 8: Next Steps for ADHD: ASCEND Trial

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 8 Next Steps for AEVI - 001: ADHD • ASCEND Trial: ADHD – Multi - center, placebo - controlled Phase 2 confirmatory trial – Patients ages 6 – 17 with 9 gene subset mutation – Three phase adaptive design – Patient screening to begin in Q3 2017, top - l

  9. Slide 9: Recruitment Strategy for ASCEND Trial

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine Confidential | 9 Recruitment Strategy for ASCEND Trial Direct to Physician Social Media Patient Communities Clinical Trial Sites Enter Website • Parent provides basic demographic information • Parent completes pre - screener to review inclusion/exclu

  10. Slide 10: ASCEND Trial Design

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 10 Dose - optimization Period (4 weeks) Screening Period (up to 4 weeks inclusive of washout, if applicable) Dose Maintenance Period (2 weeks) Follow - up Call (1 week) Visit #: 1 2 3 4 5 6 7 8/ET Dose: 100 mg BID, 200 mg BID, or 400 mg BID, Dose opt

  11. Slide 11: ASD Proof of Concept Trial Overview

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 11 ASD Proof of Concept Trial Overview • Focus on ASD patients with CNTN4 mutation – CNTN4 mutations have been associated with ASD in the literature 1,2 – Co - morbidity with ADHD identified in up to 85% of subjects across US studies 3 – Genotyping a

  12. Slide 12: AEVI-002 Program Overview

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine AEVI - 002 Program Overview

  13. Slide 13: AEVI-002: Anti-LIGHT mAb Program

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 13 AEVI - 002: Anti - LIGHT mAb Program • First - in - Class Biologic from Kyowa Hakko Kirin – Initial development in Severe Pediatric Onset IBD – Phase 2 human monoclonal antibody • Program Update – Orphan designation expected: pediatric Crohn’s Dis

  14. Slide 14: Q2 2017 Financial Update

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine Q2 2017 Financial Update

  15. Slide 15: Q2 Financial Update

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 15 Q2 17 Financial Update  R&D expenses for 2Q 17 were $5.7M, decreasing from $8.7M for the same period in 2016 mainly related to decreased spend associated with the AEVI - 001 program following conclusion of the SAGA trial.  G&A expenses for 2Q 17

  16. Slide 16: Aevi Genomic Medicine Pipeline

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine Confidential | 16 Aevi Genomic Medicine Pipeline Compound Indication Preclinical Phase 1 Phase 2 Phase 3 AEVI - 001 mGluR + Genetic Subset ADHD (pediatric, age 6 - 17) CNTN4 in Autism Spectrum Disorder AEVI - 002 (anti - LIGHT mAb ) Severe Pediatric

  17. Slide 17: Thank you

    HIGHLY CONFIDENTIAL © 2017, Aevi Genomic Medicine 17 Thank you

Aevi Genomic Medicine — Corporate Update (August 2017) on 6ix